Pfizer Inc. (NYSE:PFE) insider Douglas M. Lankler sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $36.89, for a total transaction of $1,844,500.00. Following the completion of the transaction, the insider now directly owns 133,057 shares in the company, valued at $4,908,472.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Pfizer Inc. (NYSE:PFE) traded down $0.41 during trading on Wednesday, reaching $36.35. 22,180,000 shares of the company traded hands, compared to its average volume of 28,010,000. Pfizer Inc. has a 52-week low of $31.67 and a 52-week high of $39.43. The firm has a market capitalization of $216,390.00, a PE ratio of 20.77, a P/E/G ratio of 2.06 and a beta of 0.91. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The firm had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same period last year, the business earned $0.47 earnings per share. Pfizer’s revenue was up .6% compared to the same quarter last year. research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer announced that its board has initiated a stock buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 1st. Investors of record on Friday, February 2nd were given a dividend of $0.34 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.74%. The ex-dividend date of this dividend was Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is presently 77.71%.
Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in shares of Pfizer by 2.8% during the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock valued at $16,398,445,000 after acquiring an additional 12,183,218 shares during the last quarter. Mackenzie Financial Corp increased its position in shares of Pfizer by 29,164.7% during the fourth quarter. Mackenzie Financial Corp now owns 11,481,988 shares of the biopharmaceutical company’s stock valued at $415,878,000 after acquiring an additional 11,442,753 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Pfizer by 243.5% during the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after acquiring an additional 9,339,749 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. increased its position in shares of Pfizer by 81.3% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 19,093,990 shares of the biopharmaceutical company’s stock valued at $691,583,000 after acquiring an additional 8,563,358 shares during the last quarter. Hedge funds and other institutional investors own 71.41% of the company’s stock.
Several equities analysts have recently weighed in on PFE shares. Morningstar set a $38.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. UBS Group set a $42.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research note on Wednesday, December 27th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a research note on Wednesday, January 24th. Finally, Sanford C. Bernstein set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $39.40.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.